0001735276-18-000048.txt : 20180814 0001735276-18-000048.hdr.sgml : 20180814 20180814175410 ACCESSION NUMBER: 0001735276-18-000048 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180813 FILED AS OF DATE: 20180814 DATE AS OF CHANGE: 20180814 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Soni Manmeet Singh CENTRAL INDEX KEY: 0001569769 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36407 FILM NUMBER: 181019177 MAIL ADDRESS: STREET 1: C/O PHARMACYCLICS, INC. STREET 2: 995 EAST ARQUES AVE CITY: SUNNYVALE STATE: CA ZIP: 94085 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ALNYLAM PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001178670 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 770602661 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 300 THIRD STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: (617) 551-8200 MAIL ADDRESS: STREET 1: 300 THIRD STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: ALNYLAM PHARMACEUTICALS INC DATE OF NAME CHANGE: 20020724 4 1 edgardoc.xml PRIMARY DOCUMENT X0306 4 2018-08-13 0 0001178670 ALNYLAM PHARMACEUTICALS, INC. ALNY 0001569769 Soni Manmeet Singh 300 THIRD STREET CAMBRIDGE MA 02142 0 1 0 0 Chief Financial Officer Common Stock 2017-07-25 5 J 0 2 0.0 A 2 I by Managed Account Common Stock 2017-10-16 5 J 0 11 0.0 A 13 I by Managed Account Common Stock 2018-01-17 5 J 0 6 0.0 A 19 I by Managed Account Common Stock 2018-04-16 5 J 0 28 0.0 A 47 I by Managed Account Common Stock 2018-07-10 5 J 0 36 0.0 A 83 I by Managed Account Performance Stock Option 2017 (right to buy) 52.61 2018-08-13 4 A 0 25000 0.0 A 2018-08-13 2027-05-08 Common Stock 25000 25000 D Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. On May 8, 2017, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. The shares subject to the option will vest upon the commercial launch of Alnylams first internally developed product, as approved by our compensation committee. Effective August 13, 2018, the compensation committee of the Company determined the performance criterion has been met and the option shares have vested. By: /s/ Michael P. Mason, Attorney-in-Fact For: Manmeet S Soni 2018-08-14